When you read and understand the significance of this new information....investors can only draw one conclusion, as to the success of our drug GDC 0084. …... A drug, that potentially treats mutation's in 40% of all the different types of Brain Cancers. ( If successful, it is likely to have a market cap of over $1b -it is currently capped at $30m)
------------
Dr Benjamin ELLINGSON from UCLA Jonsson Comprehensive, it would seem..... has won an award for his work on GDC 0084. He will present at this forthcoming meeting, on the Saturday, following KZA Friday's presentation.
Dr Ellingson is a world leading imaging biomarker cancer investigator - and apparently his studies on GDC 0084 have resulted in this award. See link on Dr Ellingson....and at the bottom are details of his presentation details.
The fact that this work has been undertaken by one of the best people in the world on, of all things.....biomarker studies for our drug is truly off the scale. UCLA is one of the hospitals presently undertaking part in our glioblastomas Clinical Phase 2 trial.
__________________________________________________
Multi-parametric MR-PET imaging predicts pharmacokinetics and clinical response to GDC-0084 in human recurrent NIMG-34 high-grade glioma Benjamin Ellingson Neuro-Imaging Abstract Award
KZA Price at posting:
54.0¢ Sentiment: Buy Disclosure: Held
